Michael Link

Clinical Focus

• Hematology/Oncology/Stem Cell Transplant, Pediatric
• Pediatric Hematology-Oncology

Administrative Appointments

• Director, Center for Cancer and Blood Diseases, Lucile Packard Children's Hospital at Stanford (2002 - present)
• Chief, Division of Pediatric Hematology/Oncology, Stanford University School of Medicine (2000 - present)
• Lydia J. Lee Professor in Pediatric Cancer, Stanford University (2003 - present)

Honors and Awards

• Annual Memorial Lectureship, Pediatric Cancer Research Foundation (2004)
• Ben Abelson Memorial Visiting Professor, Washington University School of Medicine (2000)
• Alpha Omega Alpha, Alpha Omega Alpha (1974)
• Phi Beta Kappa, Phi Beta Kappa (1969)

Professional Education

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. View Full Information

Current Research Interests

Hematology/Oncology, treatment of sarcomas of bone and soft tissue, biology of acute lymphoblastic leukemias, treatment of non-Hodgkin's lymphoma and Hodgkin's disease.

Clinical Trials

• A Phase 2 Open Label Trial of SGN-35 for Systemic Anaplastic Large Cell Lymphoma Recruiting
• Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin's Disease Recruiting
• Reduced Duration Standford V Chemotherapy With Low-Dose Tailored-Field Radiation For Favorable Risk Pediatric Hodgkin Lymphoma Recruiting
• Therapy for Pediatric Hodgkin Lymphoma Recruiting

Publications

• Second Malignant Neoplasms in Survivors of Pediatric Hodgkin's Lymphoma Treated With Low-Dose Radiation and Chemotherapy. O'Brien MM, Donaldson SS, Balise RR, Whittemore AS, Link MP. J Clin Oncol. 2010
• The impact of the privacy rule on cancer research: variations in attitudes and application of regulatory standards. Goss E, Link MP, Bruinooge SS, Lawrence TS, Tepper JE, Runowicz CD, Schilsky RL. J Clin Oncol. 2009; 27 (24): 4014-20
• Nodular lymphocyte-predominant Hodgkin lymphoma presenting as fulminant hepatic failure in a pediatric patient: a case report with pathologic, immunophenotypic, and molecular findings. Woolf KM, Wei MC, Link MP, Arber DA, Warnke RA. Appl Immunohistochem Mol Morphol. 2008; 16 (2): 196-201
• Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease. Donaldson SS, Link MP, Weinstein HJ, Rai SN, Brain S, Billett AL, Hurwitz CA, Krasin M, Kun LE, Marcus KC, Tarbell NJ, Young JA, Hudson MM. J Clin Oncol. 2007; 25 (3): 332-7
• Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, Conrad E, Ferguson W, Gebhardt M, Goorin AM, Harris MB, Healey J, Huvos A, Link M, Montebello J, Nadel H, Nieder M, Sato J, Siegal G, Weiner M, Wells R, Wold L, Womer R, Grier H. J Clin Oncol. 2005; 23 (9): 2004-11